AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05882903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone Dipropionate Nasal Cream 0.0644%
Description: Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
Study NCT05882903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled syringe and applicator device
Description: Cream is pre-filled to a syringe and applicator device to facilitate the topical application direct to the sinus under endoscopic guidance.
Study NCT06185530 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Detection of obstructive coronary disease
Description: Detection of obstructive coronary disease
Study NCT06185530 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection of obstructive coronary disease
Description: Detection of obstructive coronary disease
Study NCT06119412 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood pressure measurement starting with standard technique or alternative new technique. manual sphygmomanometer will be used.
Description: Each participant will have their blood pressure measured with two different techniques.
Study NCT06218433 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urothelial cancer screening using urine tumor DNA test
Description: Urine sample DNA is analyzed using a targeted sequencing panel encompassing the coding regions of 21 genes that are recurrently mutated in urothelial cancer
Study NCT06218433 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urothelial cancer screening using urine cytology (comparator)
Description: Urine cytology sample
Study NCT05199272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 23ME-00610
Description: 23ME-00610 given by IV infusion
Study NCT05035693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOVE®-C
Description: Momo- or bisegmental implantation of MOVE®-C cervical prothesis.
Study NCT06149013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MindAhead Active
Description: MindAhead's Active app focuses on increasing meaningful and enjoyable cognitive, physical, and social activities specifically adapted to patients with early cognitive decline (MCI or mild dementia). These techniques include psychoeducation (explaining the rationale, the components of behavioral activation, and protective activities), action planning (selecting activities, goal setting, activity scheduling, graded task assignment, written schedules, and step-by-step sequencing) and action/self-monitoring (assessing execution of and enjoyment in activities, monitor mood and cognitive problems), as well as value-based activation (understanding most important values, selecting activities according to these values). This process aims to enable the users to understand which activities are enjoyable and meaningful to them and how to implement these activities into their daily lives. MindAhead's Active app consists of one to five sessions per week.
Study NCT06149013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment-as-usual
Description: Depending on patient-specific clinical findings it includes antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins.
Study NCT06149013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Depending on patient-specific clinical findings it includes antidementive medication (e.g., acetylcholinesterase inhibitors), advice on protective lifestyle factors, vitamin supplementation, ergotherapy, cognitive training (including digital health apps), or statins.
Study NCT04664088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients in this group will receive acupuncture once every other day (3 days per week) over an 8-week period (a total of 24 sessions). In each session, needles will be retained for 30 minutes. The acupoints will include Baihui (DU20), Qianding (DU21), Houding (DU19), Yintang (DU29), Fengchi (GB20), Shuaigu (GB8), Tongli (HT5), Hegu (LI4), Taichong (LR3), Fenglong (ST40), Xuanzhong (GB39) and Zulinqi (GB41). The selection of acupoints is on the basis of meridian theory and patients' clinical symptoms.~Patients are not allowed to take prophylactic medications. But in case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented in the patient diary.
Study NCT04664088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Participants in this group will receive oral administration of venlafaxine 50 mg once a day for 8 weeks. In case of intolerable acute VM attacks, the patients will be instructed to take triptans as rescue medication, and the dosage of medication will be documented.
Study NCT05266950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CI-135 CAR-T cells (0.5 x 10^6 CAR-T+ cells/kg，1.0 x 10^6 CAR-T+ cells/kg)
Description: Recommended lymphodepletion regimen: cyclophosphamide (250 mg/m2/d, ×3d) and fludarabine (30 mg/m2/d, ×3d). If the patient has a hematological toxicity of grade 3 or higher, the alternative regimen is: cyclophosphamide (125mg/m2/d, ×3d) and fludarabine (15 mg/m2/d, ×3d). During lymphodepletion, physicians can give anti-myeloid drugs such as demethoxydaunorubicin or daunorubicin as appropriate.
Study NCT05528133 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Genomically Guided Radiation Therapy
Description: Participants will receive treatment 5 days per week, in once daily fractions. The total dose will be 50 Gy in 25 fractions or 42.56 Gy in 16 fractions with a boost of 10 Gy in 5 fractions to the cavity.
Study NCT05629637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Resilience Training (MBRT)
Description: MBRT is designed to enhance resilience in the presence of acute and chronic LEO stressors. MBRT will be delivered in a hybrid format. An intensive, 22-hour in-person training will be offered, followed by 4 weekly 90-minute zoom classes. The in-person portion of the training will span 3 days: 4 hours day 1, 6 hours day 2, and 6 hours day 3. MBRT contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions. MBRT is designed to address stressors inherent to police work, including critical incidents, job dissatisfaction, public scrutiny, and interpersonal, affective and behavioral challenges.
Study NCT06147921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verasone
Description: Administered by sinonasal irrigation.
Study NCT06147921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verasone
Description: Administered by sinonasal irrigation.
Study NCT06218589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Velacur
Description: Velacur is a liver ultrasound that measures hepatic fat and fibrosis through the propagation of a continuously, externally conducted shear wave. An enrolled participant may choose to do the ultrasound at the time of a clinic visit, or research visit or a scheduled radiology visit according to manufacturer's instructions by trained study staff. Fibrosis and steatosis measures will be collected from all scans.
Study NCT06218589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants who have not had an MRI within the past two years will be offered a research MRI (no contrast or sedation will be used) to measure hepatic fat and hepatic stiffness (if required). Participants who have had an MRI or liver biopsy in the past two years will use historical data comparison data. MRI data will include the PDFF hepatic fat, any assessment of fibrosis and notes of other abnormalities.
Study NCT06218589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample collection for biomarkers
Description: Biomarkers are metabolic thumbprints of how the body is behaving to different health or disease processes, some of the biomarkers can be studied from plasma or serum combined with other demographics. A lipid profile and comprehensive metabolic panel (CMP), if not obtained clinically within 4 weeks, will be collected as a standard of care.
Study NCT06218589 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver biopsy
Description: Liver biopsy data will be collected only if liver biopsy is done clinically when available and scored using the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) approach.
Study NCT06533384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
Description: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
Study NCT06533384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
Description: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
Study NCT06633406 — intervention group
Intervention type: OTHER
Intervention: Age-appropriate Wechsler Intelligence Test
Description: 2.5-6 years: Wechsler Preschool and Primary Scale of Intelligence for children (WPPSI IV)~7-16 years: Wechsler Intelligence Scale for Children (WISC V)~>17 years: Wechsler Adult Intelligence Scale (WAIS IV)
Study NCT06633406 — intervention group
Intervention type: OTHER
Intervention: Disruptive Behavior Disorders Rating Scale
Description: Dutch version of the Disruptive Behavior Disorders Rating Scale
Study NCT06633406 — intervention group
Intervention type: OTHER
Intervention: Social Responsiveness Scale
Description: 3-18 years: social responsiveness scale 2 (SRS-2)~>19 years: Social Responsiveness Scale - Adult version (SRS-A)
Study NCT05828823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodialysis twice weekly
Description: Frequency and duration of hemodialysis is tailored to the patient. Adjuvant pharmacotherapy is prescribed to maintain volume, electrolyte and acid-base homeostasis ( e.g., diuretics, sodium bicarbonate and potassium binding patiromer)
Study NCT05828823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis thrice weekly
Description: Conventional hemodialysis regimen
Study NCT04718675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB-0742
Description: Oral capsules
Study NCT05783219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Description: 4% lidocaine patch placed over the sacrum 30 minutes prior to PNE procedure
Study NCT05783219 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adhesive patch placed over the sacrum 30 minutes prior to PNE procedure
Study NCT06533384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 9 cycles of Camrelizumab as adjuvant therapy.
Description: 9 cycles of Camrelizumab as adjuvant therapy.
Study NCT00888082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 3.6 mg depot injectable preparation
Study NCT06450704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Daily walking. Participants will be given an activity band to self-monitor the number of steps they walk each day during the 12-week intervention period. Each participant must reach a certain number of daily steps with a progressive goal adjusted to the number of steps from the previous week. The goal is set considering the superior number to the median of steps of the preceding week.~Weekly combined exercise sessions (aerobic + strength exercise) 2 sessions of 60 minutes per week in a 12-week program. The exercise intervention will combine the use of elastic bands and the body weight. First, 5 minutes of warm-up; second, training circuit with low-intensity strength exercises alternating work and rest times using rhythmic music. Upper, lower and middle body exercises will alternate. The program will progress in intensity, work: rest ratio, and technical difficulty of the exercises. At the end of the main part, there will be a cool-down and stretching for 5 minutes.
Study NCT06355687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Obese patients undergoing laparoscopic cholecystectomy will receive melatonin oral (0.2 mg /kg) 45 minutes before general anesthesia.
Study NCT06355687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Supplement
Description: Obese patients undergoing laparoscopic cholecystectomy will receive placebo medication (Vitamin Supplement) 45 minutes before general anesthesia.
Study NCT05633446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PepGNP-COVID19 (One vaccination)
Description: One dose with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI
Study NCT05633446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection (One vaccination)
Description: Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
Study NCT05633446 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PepGNP-COVID19 (Two vaccinations)
Description: Two vaccinations with 7.5 nmol total peptide/dose with 38.3ug gold base particle in 50 µl WFI
Study NCT05633446 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection (Two vaccinations)
Description: Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose
Study NCT05714397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cingal
Description: A single Cingal injection will be administered by fellowship-trained physicians through ultrasound-guided injection using a 20-gauge needle into the joint space of the knee under sterile conditions. The needle track will be anesthetized with local anesthetic.
Study NCT05036460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonography
Description: The transducer will be placed over the anterior neck just above the suprasternal notch, in the transverse orientation. The position of the transducer could be adjusted to visualize both the esophagus and trachea. It will be considered as esophageal intubation if esophageal dilation or double-tract sign are noted.
Study NCT05036460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct visualization
Description: While performing the intubation, the intubator will report ETI if visualizing the tracheal tube passing through the glottis. Otherwise, it will be regarded as esophageal intubation.
Study NCT05036460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct visualization
Description: While performing the intubation, the intubator will report ETI if visualizing the tracheal tube passing through the glottis. Otherwise, it will be regarded as esophageal intubation.
Study NCT06052462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3556050
Description: Administered orally
Study NCT06046690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation Device
Description: During the first week of training, ventilator trigger sensitivity will be initiated at 20% of the patient's baseline MIP (NIF). Patients will train for 5 minutes twice a day for the first days. As the training progresses, the triggering sensitivity will be gradually increased to 30% and 40% of the initial MIP and the duration will be increased up to 30 minutes. During the training sessions, participants will be elevated to a position similar to the Semi-Fowler position at an angle of approximately 45°. Vital signs will be monitored regularly.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily.
Study NCT06046690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Device
Description: The IMT (Inspiratory Muscle Training) with device will commence at 20% of the value obtained from the NIF (Negative Inspiratory Force) measurement or the lowest pressure setting, depending on the patient's tolerance. The duration and intensity will be gradually increased. Once the participants are disconnected from the mechanical ventilator, the IMT device will be connected to the T-tube via a catheter mount with a Catheter Mount. Patients will be instructed to breathe against the resistance set on the IMT device. After completing 8 repetitions, the patient will be allowed to rest for a few minutes. This routine will be repeated for a total of 3 sets of 8 repetitions.~In addition, conventional chest physiotherapy consisting of respiratory control, diaphragmatic breathing, costal expansion exercises, postural drainage, effective coughing, in-bed ROM exercises and mobilization will be applied twice daily.
Study NCT04887311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBM-01
Description: Patients will be administered study drug daily for 9 months QD via premarked medicine cups.
Study NCT06517056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emovi Knee Kinesiography
Description: All participants will receive a KneeKG exam. This device will capture three-dimensional knee kinematics for a participant's knee, using the KneeKG system. Therapists will use these reports and suggested exercises to guide their care for participants in the Intervention group.
Study NCT05564923 — intervention group
Intervention type: DRUG
Intervention: there is no intervention
Description: there is no intervention
Study NCT05937100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Teeth will be treated by using squeezed sterile cotton pellet with 20% formcresol for 1 minute
Study NCT05937100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.The biodentine mix will be prepared according to the manufacturer's instructions and condensed lightly with a condenser on the pulp stumps
Study NCT05937100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Description: Molars will be anesthetized by local anesthesia. The rubber dam will be used for isolation. Caries will be removed by large spoon excavator. When pulpal exposure occurs, deroofing of the pulp chamber will be achieved then pulpal tissue will be amputated using sharp excavator. Hemostasis will be obtained by applying pressure with saline moist cotton pellet. If bleeding has not stopped within 5 min, tooth will be excluded from the study.Hyaluronic acid gel will be compressed against the amputated pulp for 5 minutes.
Study NCT05040464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZA capsules
Description: oral AZA capsules at a daily dose of 2.5 mg per kilogram,
Study NCT05040464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX 25 mg SC once a week
Study NCT05040464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: The lab tests are: serum albumin, C-reactive protein, thrombocytosis and haemoglobin.
Study NCT05803993 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT) Single FMT infusion
Description: Single FMT infusion via colonoscopy
Study NCT05803993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) Single FMT infusion
Description: Single FMT infusion via colonoscopy
Study NCT05881330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArtiAid Intra-articular Injection
Description: Inject ArtiAid® in the affected joint at weekly interval for 5 weeks.
Study NCT03638271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac magnetic resonance imaging
Description: Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging and compare their results.
Study NCT05174507 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: empagliflozin
Description: Empagliflozin (Jardiance®; Boehringer Ingelheim (Schweiz) GmbH) is a highly selective, reversible inhibitor of the sodium glucose co-transporter 2 (SGLT2). Treatment consists of a single oral tablet of 25 mg of empagliflozin (Jardiance®) two hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).
Study NCT05174507 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: anakinra
Description: Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra) in a 100 mg/0.67ml solution for SC injection. Treatment consists of a single subcutaneous injection of 100 mg Anakinra (Kineret®) three hours before ingestion of the mixed-meal (Ensure plus® 375 ml, 75 g carbohydrates, 562 kcal, drinking time 5 minutes).